AcelRx Makes Headway With Second Pain Drug-Device Combo
This article was originally published in Scrip
With its lead drug candidate Zalviso in US FDA limbo, AcelRx Pharmaceuticals is focused on its other late-stage pain drug ARX-04, a health care professional-administered sublingual tablet that delivered fast relief of moderate-to-severe post-surgical pain for patients enrolled in a Phase III clinical trial.
You may also be interested in...
AcelRx reports fast-acting, pain-reducing data for ARX-04 in emergency room-treated trauma patients, which is the setting that most closely resembles battlefield situations experienced by personnel in the US military – the Phase III program's co-funder.
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.